Assignee
SPRINGWORKS THERAPEUTICS INC
US·41 granted patents·30 pending applications·178 citations·filing 2020–2025
Top patents by PatentIndex Score
71 records- 0197US12011424B2Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jun 18, 2024·4 cites·6 claims
- 0297US11819487B2Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Nov 21, 2023·9 cites·21 claims
- 0397US11806322B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Nov 7, 2023·6 cites·26 claims
- 0497US11806321B2Non-linear dosing of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Nov 7, 2023·11 cites·24 claims
- 0597US11571402B2Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereofSPRINGWORKS THERAPEUTICS INC·Filed 2021·Granted Feb 7, 2023·7 cites·11 claims
- 0696US11957662B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Apr 16, 2024·8 cites·17 claims
- 0796US11951096B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Apr 9, 2024·8 cites·25 claims
- 0896US11938116B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Mar 26, 2024·8 cites·17 claims
- 0996US11925620B1Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Mar 12, 2024·8 cites·19 claims
- 1096US11925619B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Mar 12, 2024·8 cites·16 claims
- 1196US11872211B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jan 16, 2024·12 cites·22 claims
- 1296US11839595B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Dec 12, 2023·3 cites·26 claims
- 1395US12090128B2Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereofSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Sep 17, 2024·2 cites·23 claims
- 1495US12029711B1Dosage forms of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Jul 9, 2024·6 cites·30 claims
- 1595US11883375B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jan 30, 2024·2 cites·30 claims
- 1695US11427534B1Solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and uses thereofSPRINGWORKS THERAPEUTICS INC·Filed 2021·Granted Aug 30, 2022·19 cites·6 claims
- 1795US11084780B1Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereofSPRINGWORKS THERAPEUTICS INC·Filed 2021·Granted Aug 10, 2021·24 cites·15 claims
- 1894US12324791B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jun 10, 2025·1 cites·2 claims
- 1994US12138246B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Nov 12, 2024·2 cites·28 claims
- 2094US12036207B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jul 16, 2024·2 cites·18 claims
- 2194US12011435B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Jun 18, 2024·2 cites·30 claims
- 2294US12011434B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jun 18, 2024·2 cites·17 claims
- 2394US11884610B2Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereofSPRINGWORKS THERAPEUTICS INC·Filed 2022·Granted Jan 30, 2024·2 cites·6 claims
- 2494US11807611B2Chlorinated tetralin compounds and pharmaceutical compositionsSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Nov 7, 2023·3 cites·19 claims
- 2594US11612588B1Chlorinated tetralin compounds and pharmaceutical compositionsSPRINGWORKS THERAPEUTICS INC·Filed 2022·Granted Mar 28, 2023·5 cites·14 claims
- 2694US11504354B1Chlorinated tetralin compounds and pharmaceutical compositionsSPRINGWORKS THERAPEUTICS INC·Filed 2022·Granted Nov 22, 2022·8 cites·12 claims
- 2793US11844780B2Chlorinated tetralin compounds and pharmaceutical compositionsSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Dec 19, 2023·2 cites·17 claims
- 2892US12234210B2Synthesis of nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Feb 25, 2025·2 cites·4 claims
- 2992US12110277B2Synthesis of nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2022·Granted Oct 8, 2024·2 cites·13 claims
- 3090US12295925B2Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted May 13, 2025·0 cites·25 claims
- 3190US12257215B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Mar 25, 2025·0 cites·22 claims
- 3290US12220390B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Feb 11, 2025·0 cites·30 claims
- 3390US2026034099A1Chlorinated tetralin compounds and pharmaceutical compositionsSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3489US2024216305A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3589US2024216306A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3689US2024226037A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3788US12383517B2Dosage forms of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Aug 12, 2025·0 cites·22 claims
- 3888US12263146B2Non-linear dosing of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Apr 1, 2025·0 cites·15 claims
- 3985US12275688B2Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereofSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Apr 15, 2025·0 cites·20 claims
- 4084US12357597B2Dispersible formulations of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereofSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jul 15, 2025·0 cites·28 claims
- 4183US2025275932A1Treatment of neurofibromatosis type 1 (nf1) associated plexiform neurofibromas (pn) in pediatric patients with mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4281US2025387356A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4381US2025268850A1Non-linear dosing of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4481US2025387358A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4581US2025387357A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4681US2026083690A1Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benazmide and uses thereofSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4781US2025387355A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4880US12186305B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Jan 7, 2025·0 cites·16 claims
- 4980US2023091097A1Chlorinated tetralin compounds and pharmaceutical compositionsSPRINGWORKS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 5079US2026091006A1Dosage forms of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
Showing the top 50 of 71 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when SPRINGWORKS THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →